JOP20210247A1 - علاج الصداع باستخدام أجسام مضادة لـ cgrp - Google Patents
علاج الصداع باستخدام أجسام مضادة لـ cgrpInfo
- Publication number
- JOP20210247A1 JOP20210247A1 JOP/2021/0247A JOP20210247A JOP20210247A1 JO P20210247 A1 JOP20210247 A1 JO P20210247A1 JO P20210247 A JOP20210247 A JO P20210247A JO P20210247 A1 JOP20210247 A1 JO P20210247A1
- Authority
- JO
- Jordan
- Prior art keywords
- headache
- treatment
- cgrp antibodies
- cgrp
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962842162P | 2019-05-02 | 2019-05-02 | |
| US201962872989P | 2019-07-11 | 2019-07-11 | |
| PCT/US2020/012781 WO2020146527A1 (en) | 2019-01-08 | 2020-01-08 | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
| PCT/US2020/018702 WO2020222892A1 (en) | 2019-05-02 | 2020-02-18 | Treatment of headache using anti-cgrp antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20210247A1 true JOP20210247A1 (ar) | 2023-01-30 |
Family
ID=73028680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2021/0247A JOP20210247A1 (ar) | 2019-05-02 | 2020-02-18 | علاج الصداع باستخدام أجسام مضادة لـ cgrp |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220251178A1 (https=) |
| EP (1) | EP3962522A4 (https=) |
| JP (2) | JP2022533030A (https=) |
| KR (1) | KR20220004053A (https=) |
| CN (1) | CN113811326A (https=) |
| AU (1) | AU2020267107B2 (https=) |
| BR (1) | BR112020027063A2 (https=) |
| CA (1) | CA3133571A1 (https=) |
| CL (1) | CL2021002866A1 (https=) |
| DO (1) | DOP2021000215A (https=) |
| EA (1) | EA202192865A1 (https=) |
| GE (2) | GEP20257803B (https=) |
| IL (1) | IL287759A (https=) |
| JO (1) | JOP20210247A1 (https=) |
| MA (1) | MA55815A (https=) |
| MX (1) | MX2021013426A (https=) |
| PH (1) | PH12021552422A1 (https=) |
| SG (1) | SG11202110637RA (https=) |
| WO (1) | WO2020222892A1 (https=) |
| ZA (1) | ZA202106627B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL310885A (en) * | 2021-08-27 | 2024-04-01 | H Lundbeck As | Treatment of cluster headache using anti-CGRP antibodies |
| KR20240058082A (ko) | 2021-09-15 | 2024-05-03 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체 투약 및 스크리닝 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107827982B (zh) * | 2011-05-20 | 2021-07-06 | H.伦德贝克公司 | 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途 |
| PE20141787A1 (es) * | 2011-05-20 | 2014-12-07 | Alderbio Holdings Llc | Composiciones anti-cgrp y uso de las mismas |
| AU2015230933B2 (en) * | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| TWI799849B (zh) * | 2015-04-24 | 2023-04-21 | 美商安美基公司 | 治療或預防偏頭痛之方法 |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| EP3448427A1 (en) * | 2016-04-29 | 2019-03-06 | CureVac AG | Rna encoding an antibody |
| CN109952314A (zh) * | 2016-09-23 | 2019-06-28 | 泰瓦制药国际有限公司 | 治疗难治性偏头痛 |
| WO2020146527A1 (en) * | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
-
2020
- 2020-02-18 KR KR1020217035290A patent/KR20220004053A/ko active Pending
- 2020-02-18 EP EP20798303.2A patent/EP3962522A4/en active Pending
- 2020-02-18 CN CN202080030955.5A patent/CN113811326A/zh active Pending
- 2020-02-18 MA MA055815A patent/MA55815A/fr unknown
- 2020-02-18 AU AU2020267107A patent/AU2020267107B2/en active Active
- 2020-02-18 CA CA3133571A patent/CA3133571A1/en active Pending
- 2020-02-18 JP JP2021564691A patent/JP2022533030A/ja active Pending
- 2020-02-18 EA EA202192865A patent/EA202192865A1/ru unknown
- 2020-02-18 MX MX2021013426A patent/MX2021013426A/es unknown
- 2020-02-18 BR BR112020027063A patent/BR112020027063A2/pt unknown
- 2020-02-18 PH PH1/2021/552422A patent/PH12021552422A1/en unknown
- 2020-02-18 US US17/608,220 patent/US20220251178A1/en active Pending
- 2020-02-18 GE GEAP202015803A patent/GEP20257803B/en unknown
- 2020-02-18 WO PCT/US2020/018702 patent/WO2020222892A1/en not_active Ceased
- 2020-02-18 GE GEAP202515803A patent/GEAP202515803A/en unknown
- 2020-02-18 SG SG11202110637RA patent/SG11202110637RA/en unknown
- 2020-02-18 JO JOP/2021/0247A patent/JOP20210247A1/ar unknown
-
2021
- 2021-09-08 ZA ZA2021/06627A patent/ZA202106627B/en unknown
- 2021-10-19 DO DO2021000215A patent/DOP2021000215A/es unknown
- 2021-10-29 CL CL2021002866A patent/CL2021002866A1/es unknown
- 2021-11-01 IL IL287759A patent/IL287759A/en unknown
-
2025
- 2025-10-16 JP JP2025174054A patent/JP2026016471A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220004053A (ko) | 2022-01-11 |
| MA55815A (fr) | 2022-03-09 |
| CL2021002866A1 (es) | 2022-06-17 |
| AU2020267107A1 (en) | 2021-10-07 |
| EP3962522A4 (en) | 2023-07-19 |
| BR112020027063A2 (pt) | 2021-11-16 |
| ZA202106627B (en) | 2025-12-17 |
| CA3133571A1 (en) | 2020-11-05 |
| IL287759A (en) | 2022-01-01 |
| JP2026016471A (ja) | 2026-02-03 |
| GEP20257803B (en) | 2025-10-10 |
| EA202192865A1 (ru) | 2022-02-14 |
| PH12021552422A1 (en) | 2022-07-11 |
| WO2020222892A1 (en) | 2020-11-05 |
| GEAP202515803A (en) | 2025-06-10 |
| EP3962522A1 (en) | 2022-03-09 |
| JP2022533030A (ja) | 2022-07-21 |
| US20220251178A1 (en) | 2022-08-11 |
| CN113811326A (zh) | 2021-12-17 |
| MX2021013426A (es) | 2021-12-10 |
| SG11202110637RA (en) | 2021-10-28 |
| AU2020267107B2 (en) | 2026-04-09 |
| DOP2021000215A (es) | 2021-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551478A1 (en) | Acute treatment and rapid treatment of headache using anti-cgrp antibodies | |
| PH12021551494A1 (en) | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| JOP20190283B1 (ar) | طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها | |
| CO2017000571A2 (es) | Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena | |
| SA518400222B1 (ar) | أجسام مضادة لـ وتركيبات tim-3 | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| CY1122456T1 (el) | Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου | |
| MX2019009660A (es) | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. | |
| MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
| EP3964527A3 (en) | Combination therapy for cancer | |
| WO2018160896A8 (en) | Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide | |
| JO3559B1 (ar) | جسم مضاد لعلاج أو الوقاية من الصداع النصفي وطريقة استخدامه | |
| EA201691683A1 (ru) | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме | |
| EP4285917A3 (en) | Monoclonal antibodies against her2 epitope and methods of use thereof | |
| SA520420109B1 (ar) | أجسام مضادة | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use | |
| AU2017310412A8 (en) | Method of improving connective tissue attachment using anti-sclerostin antibodies | |
| NZ762312A (en) | Anti-pacap antibody | |
| WO2020036646A3 (en) | Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy | |
| JOP20210247A1 (ar) | علاج الصداع باستخدام أجسام مضادة لـ cgrp | |
| MX2019014090A (es) | Métodos para el tratamiento de la reservoritis crónica. | |
| MY200803A (en) | Mpo inhibitors for use in medicine | |
| WO2020186111A3 (en) | Vista-binding antibodies and uses thereof |